CCR2 promotes hepatic fibrosis in mice

Ekihiro Seki, Samuele de Minicis, Sayaka Inokuchi, Kojiro Taura, Katsumi Miyai, Nico van Rooijen, Robert F. Schwabe, David A. Brenner – 23 June 2009 – Chemokines and chemokine receptors contribute to the migration of hepatic stellate cells (HSCs) and Kupffer cells, two key cell types in fibrogenesis. Here, we investigate the role of CCR2, the receptor for monocyte chemoattractant protein (MCP)‐1, MCP‐2, and MCP‐3, in hepatic fibrosis. Hepatic CCR2, MCP‐1, MCP‐2, and MCP‐3 messenger RNA expression was increased after bile duct ligation (BDL).

Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis

Stephen H. Caldwell, Luiz Antonio R. de Freitas, Sang H. Park, Maria Lucia V. Moreno, Jan A. Redick, Christine A. Davis, Barbee J. Sisson, James T. Patrie, Helma Cotrim, Curtis K. Argo, Abdullah Al‐Osaimi – 28 May 2009 – Mitochondrial dysfunction is an important element in the pathogenesis of nonalcoholic steatohepatitis (NASH). Intramitochondrial crystals (IMCs) are a well‐documented morphological abnormality seen on transmission electron microscopy in this disease.

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice

Emina Halilbasic, Romina Fiorotto, Peter Fickert, Hanns‐Ulrich Marschall, Tarek Moustafa, Carlo Spirli, Andrea Fuchsbichler, Judith Gumhold, Dagmar Silbert, Kurt Zatloukal, Cord Langner, Uday Maitra, Helmut Denk, Alan F. Hofmann, Mario Strazzabosco, Michael Trauner – 28 May 2009 – 24‐norursodeoxycholic acid (norUDCA), a side chain–modified ursodeoxycholic acid derivative, has dramatic therapeutic effects in experimental cholestasis and may be a promising agent for the treatment of cholestatic liver diseases.

Methodological reporting of randomized clinical trials in major gastroenterology and hepatology journals in 2006

Yu Bai, Jun Gao, Duo‐Wu Zou, Zhao‐Shen Li – 28 May 2009 – To determine the current quality of reporting of randomized clinical trials (RCTs) in the field of gastroenterology and hepatology, we evaluated the methodological reporting of RCTs in six major gastroenterology and hepatology journals.

Long‐term outcome of hepatitis B e antigen–negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time

Dar‐In Tai, Shi‐Ming Lin, I‐Shyan Sheen, Chia‐Ming Chu, Deng‐Yn Lin, Yun‐Fan Liaw – 28 May 2009 – The baseline alanine aminotransferase (ALT) level was reported to have prognostic value in chronic hepatitis B virus (HBV) infection, during which ALT may change over time. Instead of baseline ALT, this study aimed to study the prognostic value of the height of ALT during the course of chronic HBV infection.

Subscribe to